SCHEMBL6694889

SCHEMBL6694889

NC(=O)N=S(=O)=O.NS(=O)(=O)c1ncc[nH]1

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CSNK1A1 P48729 1/20 0.32
TYRO3 Q06418 1/20 0.32
DYRK1B Q9Y463 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL626944 0.81
SCHEMBL6692094 0.76 NPC1 (0.39) CSNK1A1TYRO3DYRK1B
Alcohol SCHEMBL27365728 0.73 CA1 (0.35) CA1CA2
SCHEMBL28416612 0.71
SCHEMBL914628 0.67 CSNK1A1 (0.35) CSNK1A1TYRO3DYRK1B
SCHEMBL29868523 0.66
SCHEMBL30821606 0.66 L3MBTL1 (0.38) CA1CA2CSNK1A1TYRO3DYRK1B
SCHEMBL329285 0.66
SCHEMBL502541 0.65 TXNRD1 (0.44) CA1CA2
Hydrochloric Acid SCHEMBL27594552 0.64 L3MBTL1 (0.37) CA1CA2CSNK1A1TYRO3DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040006118-A1 Nf-kb inhibitors SMITHKLINE BEECHAM CORPORATION 2004-01-08 US disclosed
EP-1328272-A1 NF-KAPPA-B INHIBITORS SmithKline Beecham Corporation (US) 2003-07-23 EP disclosed
WO-2002030423-A1 NF-λB INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006118-A1 Nf-kb inhibitors NFKBIA, IKBKB, IKBKG CA1 4861/4885CA2 4706/4885CSNK1A1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.